Cutis is a peer-reviewed clinical journal for the dermatologist, allergist, and general practitioner published monthly since 1965. Concise clinical articles present the practical side of dermatology, helping physicians to improve patient care. Cutis is referenced in Index Medicus/MEDLINE and is written and edited by industry leaders.

Top Sections
Coding
Dermpath Diagnosis
For Residents
Photo Challenge
Tips
ct
Main menu
CUTIS Main Menu
Explore menu
CUTIS Explore Menu
Proclivity ID
18823001
Unpublish
Negative Keywords
ammunition
ass lick
assault rifle
balls
ballsac
black jack
bleach
Boko Haram
bondage
causas
cheap
child abuse
cocaine
compulsive behaviors
cost of miracles
cunt
Daech
display network stats
drug paraphernalia
explosion
fart
fda and death
fda AND warn
fda AND warning
fda AND warns
feom
fuck
gambling
gfc
gun
human trafficking
humira AND expensive
illegal
ISIL
ISIS
Islamic caliphate
Islamic state
madvocate
masturbation
mixed martial arts
MMA
molestation
national rifle association
NRA
nsfw
nuccitelli
pedophile
pedophilia
poker
porn
porn
pornography
psychedelic drug
recreational drug
sex slave rings
shit
slot machine
snort
substance abuse
terrorism
terrorist
texarkana
Texas hold 'em
UFC
Negative Keywords Excluded Elements
div[contains(@class, 'alert ad-blocker')]
section[contains(@class, 'nav-hidden')]
section[contains(@class, 'nav-hidden active')
Altmetric
DSM Affiliated
Display in offset block
Disqus Exclude
Best Practices
CE/CME
Education Center
Medical Education Library
Enable Disqus
Display Author and Disclosure Link
Publication Type
Clinical
Slot System
Featured Buckets
Disable Sticky Ads
Disable Ad Block Mitigation
Featured Buckets Admin
Show Ads on this Publication's Homepage
Consolidated Pub
Show Article Page Numbers on TOC
Expire Announcement Bar
Use larger logo size
Off
publication_blueconic_enabled
Off
Show More Destinations Menu
Disable Adhesion on Publication
Off
Restore Menu Label on Mobile Navigation
Disable Facebook Pixel from Publication
Exclude this publication from publication selection on articles and quiz
Gating Strategy
First Page Free
Challenge Center
Disable Inline Native ads
survey writer start date
Current Issue
Title
Cutis
Description

A peer-reviewed, indexed journal for dermatologists with original research, image quizzes, cases and reviews, and columns.

Current Issue Reference

Alpha-1 Foundation Announces Funding Opportunities

Article Type
Changed
Display Headline
Alpha-1 Foundation Announces Funding Opportunities

The Alpha-1 Foundation has announced its funding opportunities in its 2017-2018 grants cycle. In-cycle Letters of Intent are due by September 22, 2017, and may be submitted online.

Publications
Topics
Sections

The Alpha-1 Foundation has announced its funding opportunities in its 2017-2018 grants cycle. In-cycle Letters of Intent are due by September 22, 2017, and may be submitted online.

The Alpha-1 Foundation has announced its funding opportunities in its 2017-2018 grants cycle. In-cycle Letters of Intent are due by September 22, 2017, and may be submitted online.

Publications
Publications
Topics
Article Type
Display Headline
Alpha-1 Foundation Announces Funding Opportunities
Display Headline
Alpha-1 Foundation Announces Funding Opportunities
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

NORD Welcomes All Things Kabuki as New Member

Article Type
Changed
Display Headline
NORD Welcomes All Things Kabuki as New Member

All Things Kabuki, an organization providing awareness, education, and support on behalf of those affected by Kabuki syndrome, is NORD’s newest member organization. Read NORD’s Rare Disease Database report on Kabuki syndrome.

Publications
Topics
Sections

All Things Kabuki, an organization providing awareness, education, and support on behalf of those affected by Kabuki syndrome, is NORD’s newest member organization. Read NORD’s Rare Disease Database report on Kabuki syndrome.

All Things Kabuki, an organization providing awareness, education, and support on behalf of those affected by Kabuki syndrome, is NORD’s newest member organization. Read NORD’s Rare Disease Database report on Kabuki syndrome.

Publications
Publications
Topics
Article Type
Display Headline
NORD Welcomes All Things Kabuki as New Member
Display Headline
NORD Welcomes All Things Kabuki as New Member
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information

Article Type
Changed
Display Headline
Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information

An article on the Columbia University Medical Center website describes how neurosurgeon Jeffrey Bruce, MD, helped NORD develop a report for patient/family education on anaplastic astrocytoma. Dr. Bruce is one of many rare disease medical experts who volunteer their time and expertise to help NORD provide information on rare conditions for patients and their families.

Publications
Topics
Sections

An article on the Columbia University Medical Center website describes how neurosurgeon Jeffrey Bruce, MD, helped NORD develop a report for patient/family education on anaplastic astrocytoma. Dr. Bruce is one of many rare disease medical experts who volunteer their time and expertise to help NORD provide information on rare conditions for patients and their families.

An article on the Columbia University Medical Center website describes how neurosurgeon Jeffrey Bruce, MD, helped NORD develop a report for patient/family education on anaplastic astrocytoma. Dr. Bruce is one of many rare disease medical experts who volunteer their time and expertise to help NORD provide information on rare conditions for patients and their families.

Publications
Publications
Topics
Article Type
Display Headline
Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information
Display Headline
Columbia Neurosurgery Article Highlights Medical Expert’s Support for NORD Patient Information
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

FDA Launches Expanded Access Navigator

Article Type
Changed
Display Headline
FDA Launches Expanded Access Navigator

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Publications
Topics
Sections

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Patients with serious or immediately life-threatening diseases or conditions who have no comparable or satisfactory alternative therapy and who seek access to potentially life-saving investigational drugs can use the FDA’s new Expanded Access Navigator to guide them through the process. The Navigator was a team effort led by the Reagan-Udall Foundation in collaboration with patient advocacy groups, the pharmaceutical industry, the FDA, and others in the Federal government.

Publications
Publications
Topics
Article Type
Display Headline
FDA Launches Expanded Access Navigator
Display Headline
FDA Launches Expanded Access Navigator
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Examining the Role of Caregivers at NINR Caregiving Summit

Article Type
Changed

Mary Dunkle, NORD Vice President of Educational Initiatives, will speak on a panel discussing the role and needs of caregivers at “The Science of Caregiving: Bringing Voices Together” to be hosted by the National Institute of Nursing Research (NINR) on August 7-8, 2017, in Bethesda, Maryland. This conference is open to all and will also be livestreamed and archived for on-demand viewing. 

Publications
Topics
Sections

Mary Dunkle, NORD Vice President of Educational Initiatives, will speak on a panel discussing the role and needs of caregivers at “The Science of Caregiving: Bringing Voices Together” to be hosted by the National Institute of Nursing Research (NINR) on August 7-8, 2017, in Bethesda, Maryland. This conference is open to all and will also be livestreamed and archived for on-demand viewing. 

Mary Dunkle, NORD Vice President of Educational Initiatives, will speak on a panel discussing the role and needs of caregivers at “The Science of Caregiving: Bringing Voices Together” to be hosted by the National Institute of Nursing Research (NINR) on August 7-8, 2017, in Bethesda, Maryland. This conference is open to all and will also be livestreamed and archived for on-demand viewing. 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

FDA Commissioner to Present Keynote Address at NORD Summit

Article Type
Changed
Display Headline
FDA Commissioner to Present Keynote Address at NORD Summit

Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will present the keynote address in the opening session of the 2017 NORD Summit. Dr. Gottlieb, who was sworn in as FDA Commissioner in May 2017, previously served as FDA’s Deputy Commissioner for Medical and Scientific Affairs. Before that, he was Senior Adviser to the FDA Commissioner.

Mike Porath, award-winning journalist and founder/CEO of The Mighty, will present the patient keynote. He has held writing, editing, and executive positions at ABC News, NBC News, the New York Times, and AOL. Mr. Porath is the father of a child with Dup15q syndrome and sits on the board of Dup15q Alliance.

Publications
Topics
Sections

Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will present the keynote address in the opening session of the 2017 NORD Summit. Dr. Gottlieb, who was sworn in as FDA Commissioner in May 2017, previously served as FDA’s Deputy Commissioner for Medical and Scientific Affairs. Before that, he was Senior Adviser to the FDA Commissioner.

Mike Porath, award-winning journalist and founder/CEO of The Mighty, will present the patient keynote. He has held writing, editing, and executive positions at ABC News, NBC News, the New York Times, and AOL. Mr. Porath is the father of a child with Dup15q syndrome and sits on the board of Dup15q Alliance.

Food and Drug Administration (FDA) Commissioner Scott Gottlieb, MD, will present the keynote address in the opening session of the 2017 NORD Summit. Dr. Gottlieb, who was sworn in as FDA Commissioner in May 2017, previously served as FDA’s Deputy Commissioner for Medical and Scientific Affairs. Before that, he was Senior Adviser to the FDA Commissioner.

Mike Porath, award-winning journalist and founder/CEO of The Mighty, will present the patient keynote. He has held writing, editing, and executive positions at ABC News, NBC News, the New York Times, and AOL. Mr. Porath is the father of a child with Dup15q syndrome and sits on the board of Dup15q Alliance.

Publications
Publications
Topics
Article Type
Display Headline
FDA Commissioner to Present Keynote Address at NORD Summit
Display Headline
FDA Commissioner to Present Keynote Address at NORD Summit
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products

Article Type
Changed
Display Headline
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products Breakthrough Summit

Promoting Earlier Diagnosis, the Power of Data Sharing, Next-Generation Treatments, and Advancing Clinical Trials will be among the topics discussed at the 2017 NORD Rare Diseases and Orphan Products Breakthrough Summit, to be held on October 16-17, 2017, in Washington DC. The program is open to all and will feature more than 80 expert speakers. Learn more and download the agenda

Register by August 25 for Early-Bird Pricing

Online registration is now open for the NORD Summit. Register by August 25 to save up to $400. The NORD Summit will take place October 16-17 at the Marriott Wardman Park Hotel in Washington DC. 

Submit a Poster Abstract or Become an Exhibitor or Sponsor

August 18 is the deadline to submit abstracts for the Summit Poster Session. The overall poster theme is “Life-Transforming Treatments.” In addition, there are opportunities to exhibit at the Summit or become a sponsor. Exhibiting and sponsorship inquiries may be sent to [email protected].  

Publications
Topics
Sections

Promoting Earlier Diagnosis, the Power of Data Sharing, Next-Generation Treatments, and Advancing Clinical Trials will be among the topics discussed at the 2017 NORD Rare Diseases and Orphan Products Breakthrough Summit, to be held on October 16-17, 2017, in Washington DC. The program is open to all and will feature more than 80 expert speakers. Learn more and download the agenda

Register by August 25 for Early-Bird Pricing

Online registration is now open for the NORD Summit. Register by August 25 to save up to $400. The NORD Summit will take place October 16-17 at the Marriott Wardman Park Hotel in Washington DC. 

Submit a Poster Abstract or Become an Exhibitor or Sponsor

August 18 is the deadline to submit abstracts for the Summit Poster Session. The overall poster theme is “Life-Transforming Treatments.” In addition, there are opportunities to exhibit at the Summit or become a sponsor. Exhibiting and sponsorship inquiries may be sent to [email protected].  

Promoting Earlier Diagnosis, the Power of Data Sharing, Next-Generation Treatments, and Advancing Clinical Trials will be among the topics discussed at the 2017 NORD Rare Diseases and Orphan Products Breakthrough Summit, to be held on October 16-17, 2017, in Washington DC. The program is open to all and will feature more than 80 expert speakers. Learn more and download the agenda

Register by August 25 for Early-Bird Pricing

Online registration is now open for the NORD Summit. Register by August 25 to save up to $400. The NORD Summit will take place October 16-17 at the Marriott Wardman Park Hotel in Washington DC. 

Submit a Poster Abstract or Become an Exhibitor or Sponsor

August 18 is the deadline to submit abstracts for the Summit Poster Session. The overall poster theme is “Life-Transforming Treatments.” In addition, there are opportunities to exhibit at the Summit or become a sponsor. Exhibiting and sponsorship inquiries may be sent to [email protected].  

Publications
Publications
Topics
Article Type
Display Headline
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products Breakthrough Summit
Display Headline
Preview Agenda for NORD’s 2017 Rare Diseases and Orphan Products Breakthrough Summit
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default

Paraneoplastic Acrokeratosis Bazex Syndrome: Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin

Article Type
Changed
Display Headline
Paraneoplastic Acrokeratosis (Bazex Syndrome): Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin

To the Editor:

Paraneoplastic acrokeratosis (PA), also known as Bazex syndrome, is a rare paraneoplastic dermatosis first described in 1965 by Bazex et al.1 This entity is clinically characterized by dusky erythematous to violaceous keratoderma of the acral sites and commonly affects men older than 40 years. In most reported cases, there has been an underlying primary malignant neoplasm of the upper aerodigestive tract2; however, some other associated malignancies also have been reported. Skin changes tend to occur before the diagnosis of the associated tumor in 67% of cases. The cutaneous lesions usually resolve after successful treatment of the tumor and relapse in case of recurrence of the malignancy.3

A 53-year-old woman who was a smoker with no relevant medical background was referred to the dermatology department with an itching psoriasiform dermatitis on the palms and soles of 2 months' duration. There were no signs of systemic disease. Physical examination revealed well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (Figure, A). Scattered symmetric hyperkeratotic plaques were present on the palms (Figure, B). We also detected onychodystrophy on the hands. Other dermatologic findings were normal. Histologic examination of a biopsy specimen of the left sole showed hyperkeratosis, focal parakeratosis, acanthosis, hypergranulosis, and a predominantly perivascular dermal lymphocytic infiltrate.

Paraneoplastic acrokeratosis with well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (A) and symmetric hyperkeratotic plaques on the palms (B).

With the diagnostic suspicion of PA, blood tests, chest radiograph, and colonoscopy were performed without revealing abnormalities. Positron emission tomography and computed tomography also was performed, showing cervical, mesenteric, retroperitoneal, and inguinal adenopathies. Histologic examination of both inguinal adenectomy and cervical lymph node biopsy revealed Bcl-2-positive in situ follicular lymphoma (ISFL). Examination of an iliac crest marrow aspirate showed minimal involvement of lymphoma (10%). Follow-up imaging performed 4 months after diagnosis showed no changes. The patient was diagnosed with a low-grade chronic lymphoproliferative disorder with histologic findings consistent with ISFL presenting with small disperse adenopathies and minimal bone marrow involvement. The hematology department opted for a wait-and-see approach with 6-month follow-up imaging.

The skin lesions were first treated with salicylic acid cream 10%, psoralen plus UVA therapy, and methotrexate 20 mg weekly for 2 months without remission. Replacing the other therapies, we initiated acitretin 25 mg daily, achieving sustained remission after 6 months of treatment, and then continued with a scaled dose reduction. The patient remained lesion free 1 year after starting the treatment, with a daily dose of 10 mg of acitretin.

Paraneoplastic acrokeratosis has been traditionally described as a paraneoplastic entity mainly associated with primary squamous cell carcinoma (SCC) of the upper aerodigestive tract or a metastatic SCC of the cervical lymph nodes with an unknown origin.4,5 However, uncommon associations such as adenocarcinoma of the prostate, lung, esophagus, stomach, and colon; transitional cell carcinoma of the bladder; small cell carcinoma of the lung; cutaneous SCC; breast cancer; metastatic thymic carcinoma; metastatic neuroendocrine tumor; bronchial carcinoid tumor; SCC of the vulvar region; simultaneous multiple genitourinary tumors; and liposarcoma also have been described.6 Regarding the association with lymphoma, PA has been reported with peripheral T-cell lymphoma7 and Hodgkin disease8; however, ISFL underlying PA is rare.

Follicular lymphoma is the second most common non-Hodgkin lymphoma in Western countries and comprises approximately 20% of all lymphomas.9 It is slightly more prevalent in females, and the majority of patients present with advanced-stage disease. Generally considered to be an incurable disease, a watchful-waiting approach of conservative management has been advocated in most cases, deferring treatment until symptoms appear.9

Histology of PA is nonspecific, as in our case. However, it facilitates a differential diagnosis of major dermatoses including psoriasis vulgaris, pityriasis rubra pilaris, and lupus erythematosus.

Paraneoplastic palmoplantar keratoderma also is characteristic of Howel-Evans syndrome, which is a rare inherited condition associated with esophageal cancer. In contrast to our case, palmoplantar keratoderma in these patients usually begins around 10 years of age, is caused by a mutation in the RHBDF2 gene, and is inherited in an autosomal pattern.10

The diagnosis in our case was supported by a typical clinical picture, nonspecific histology, and the concurrent finding of the underlying lymphoma. Treatment of PA must focus on the removal of the underlying malignancy, which implies the remission of the cutaneous lesions. Taking into account that a recurrence of the primary tumor leads to a relapse of skin manifestations while distant metastases do not cause a reappearance of PA, it could be suggested that pathogenetically relevant factors are produced by the primary tumor and by lymph node metastases but not by metastases elsewhere.

In this case, due to the wait-and-see approach, a specific treatment for the skin lesions was established. Although management of the skin itself generally is ineffective, there are isolated reports of response after corticosteroids, antibiotics, antimycotics, keratolytic measures, or psoralen plus UVA therapy.6 Wishart11 used etretinate to achieve an improvement of PA. We also achieved good response with acitretin. Retinoids are known to have antineoplastic activity, which may have been helpful in both the patient we presented and the one reported by Wishart.11 In summary, we propose adding ISFL to the expanding list of malignant neoplasms associated with PA, noting the response of skin lesions after acitretin.

References
  1. Bazex A, Salvador R, Dupré A, et al. Syndrome paranéoplasique à type d'hyperkératose des extremités. Guérison après le traitement de l'épithelioma laryngé. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.
  2. Bazex A, Griffiths A. Acrokeratosis paraneoplasticae--a new cutaneous marker of malignancy. Br J Dermatol. 1980;103:301-306.
  3. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14:84-89.
  4. Witkowski JA, Parish LC. Bazex's syndrome. Paraneoplastic acrokeratosis. JAMA. 1982;248:2883-2884.
  5. Bolognia JL. Bazex's syndrome. Clin Dermatol. 1993;11:37-42.
  6. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma [published online August 28, 2006]. J Am Acad Dermatol. 2006;55:1103-1105.
  7. Lin YC, Chu CY, Chiu HC. Acrokeratosis paraneoplastica Bazex's  syndrome: unusual association with a peripheral T-cell lymphoma. Acta Derm Venereol. 2001;81:440-441.
  8. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol. 1995;133:322-325.
  9. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976-2984.
  10. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85:183-185.
  11. Wishart JM. Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol. 1986;115:595-599.
Article PDF
Author and Disclosure Information

Dr. Conde-Montero is from the Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid. Drs. Baniandrés-Rodríguez, Horcajada-Reales, Parra-Blanco, and Suárez-Fernández are from the Department of Dermatology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

The authors report no conflict of interest.

Correspondence: Elena Conde-Montero, MD ([email protected]).

Issue
Cutis - 100(2)
Publications
Topics
Page Number
E3-E5
Sections
Author and Disclosure Information

Dr. Conde-Montero is from the Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid. Drs. Baniandrés-Rodríguez, Horcajada-Reales, Parra-Blanco, and Suárez-Fernández are from the Department of Dermatology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

The authors report no conflict of interest.

Correspondence: Elena Conde-Montero, MD ([email protected]).

Author and Disclosure Information

Dr. Conde-Montero is from the Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid. Drs. Baniandrés-Rodríguez, Horcajada-Reales, Parra-Blanco, and Suárez-Fernández are from the Department of Dermatology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

The authors report no conflict of interest.

Correspondence: Elena Conde-Montero, MD ([email protected]).

Article PDF
Article PDF

To the Editor:

Paraneoplastic acrokeratosis (PA), also known as Bazex syndrome, is a rare paraneoplastic dermatosis first described in 1965 by Bazex et al.1 This entity is clinically characterized by dusky erythematous to violaceous keratoderma of the acral sites and commonly affects men older than 40 years. In most reported cases, there has been an underlying primary malignant neoplasm of the upper aerodigestive tract2; however, some other associated malignancies also have been reported. Skin changes tend to occur before the diagnosis of the associated tumor in 67% of cases. The cutaneous lesions usually resolve after successful treatment of the tumor and relapse in case of recurrence of the malignancy.3

A 53-year-old woman who was a smoker with no relevant medical background was referred to the dermatology department with an itching psoriasiform dermatitis on the palms and soles of 2 months' duration. There were no signs of systemic disease. Physical examination revealed well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (Figure, A). Scattered symmetric hyperkeratotic plaques were present on the palms (Figure, B). We also detected onychodystrophy on the hands. Other dermatologic findings were normal. Histologic examination of a biopsy specimen of the left sole showed hyperkeratosis, focal parakeratosis, acanthosis, hypergranulosis, and a predominantly perivascular dermal lymphocytic infiltrate.

Paraneoplastic acrokeratosis with well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (A) and symmetric hyperkeratotic plaques on the palms (B).

With the diagnostic suspicion of PA, blood tests, chest radiograph, and colonoscopy were performed without revealing abnormalities. Positron emission tomography and computed tomography also was performed, showing cervical, mesenteric, retroperitoneal, and inguinal adenopathies. Histologic examination of both inguinal adenectomy and cervical lymph node biopsy revealed Bcl-2-positive in situ follicular lymphoma (ISFL). Examination of an iliac crest marrow aspirate showed minimal involvement of lymphoma (10%). Follow-up imaging performed 4 months after diagnosis showed no changes. The patient was diagnosed with a low-grade chronic lymphoproliferative disorder with histologic findings consistent with ISFL presenting with small disperse adenopathies and minimal bone marrow involvement. The hematology department opted for a wait-and-see approach with 6-month follow-up imaging.

The skin lesions were first treated with salicylic acid cream 10%, psoralen plus UVA therapy, and methotrexate 20 mg weekly for 2 months without remission. Replacing the other therapies, we initiated acitretin 25 mg daily, achieving sustained remission after 6 months of treatment, and then continued with a scaled dose reduction. The patient remained lesion free 1 year after starting the treatment, with a daily dose of 10 mg of acitretin.

Paraneoplastic acrokeratosis has been traditionally described as a paraneoplastic entity mainly associated with primary squamous cell carcinoma (SCC) of the upper aerodigestive tract or a metastatic SCC of the cervical lymph nodes with an unknown origin.4,5 However, uncommon associations such as adenocarcinoma of the prostate, lung, esophagus, stomach, and colon; transitional cell carcinoma of the bladder; small cell carcinoma of the lung; cutaneous SCC; breast cancer; metastatic thymic carcinoma; metastatic neuroendocrine tumor; bronchial carcinoid tumor; SCC of the vulvar region; simultaneous multiple genitourinary tumors; and liposarcoma also have been described.6 Regarding the association with lymphoma, PA has been reported with peripheral T-cell lymphoma7 and Hodgkin disease8; however, ISFL underlying PA is rare.

Follicular lymphoma is the second most common non-Hodgkin lymphoma in Western countries and comprises approximately 20% of all lymphomas.9 It is slightly more prevalent in females, and the majority of patients present with advanced-stage disease. Generally considered to be an incurable disease, a watchful-waiting approach of conservative management has been advocated in most cases, deferring treatment until symptoms appear.9

Histology of PA is nonspecific, as in our case. However, it facilitates a differential diagnosis of major dermatoses including psoriasis vulgaris, pityriasis rubra pilaris, and lupus erythematosus.

Paraneoplastic palmoplantar keratoderma also is characteristic of Howel-Evans syndrome, which is a rare inherited condition associated with esophageal cancer. In contrast to our case, palmoplantar keratoderma in these patients usually begins around 10 years of age, is caused by a mutation in the RHBDF2 gene, and is inherited in an autosomal pattern.10

The diagnosis in our case was supported by a typical clinical picture, nonspecific histology, and the concurrent finding of the underlying lymphoma. Treatment of PA must focus on the removal of the underlying malignancy, which implies the remission of the cutaneous lesions. Taking into account that a recurrence of the primary tumor leads to a relapse of skin manifestations while distant metastases do not cause a reappearance of PA, it could be suggested that pathogenetically relevant factors are produced by the primary tumor and by lymph node metastases but not by metastases elsewhere.

In this case, due to the wait-and-see approach, a specific treatment for the skin lesions was established. Although management of the skin itself generally is ineffective, there are isolated reports of response after corticosteroids, antibiotics, antimycotics, keratolytic measures, or psoralen plus UVA therapy.6 Wishart11 used etretinate to achieve an improvement of PA. We also achieved good response with acitretin. Retinoids are known to have antineoplastic activity, which may have been helpful in both the patient we presented and the one reported by Wishart.11 In summary, we propose adding ISFL to the expanding list of malignant neoplasms associated with PA, noting the response of skin lesions after acitretin.

To the Editor:

Paraneoplastic acrokeratosis (PA), also known as Bazex syndrome, is a rare paraneoplastic dermatosis first described in 1965 by Bazex et al.1 This entity is clinically characterized by dusky erythematous to violaceous keratoderma of the acral sites and commonly affects men older than 40 years. In most reported cases, there has been an underlying primary malignant neoplasm of the upper aerodigestive tract2; however, some other associated malignancies also have been reported. Skin changes tend to occur before the diagnosis of the associated tumor in 67% of cases. The cutaneous lesions usually resolve after successful treatment of the tumor and relapse in case of recurrence of the malignancy.3

A 53-year-old woman who was a smoker with no relevant medical background was referred to the dermatology department with an itching psoriasiform dermatitis on the palms and soles of 2 months' duration. There were no signs of systemic disease. Physical examination revealed well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (Figure, A). Scattered symmetric hyperkeratotic plaques were present on the palms (Figure, B). We also detected onychodystrophy on the hands. Other dermatologic findings were normal. Histologic examination of a biopsy specimen of the left sole showed hyperkeratosis, focal parakeratosis, acanthosis, hypergranulosis, and a predominantly perivascular dermal lymphocytic infiltrate.

Paraneoplastic acrokeratosis with well-demarcated, dusky red, thick, scaly plaques on the soles with sparing of the insteps (A) and symmetric hyperkeratotic plaques on the palms (B).

With the diagnostic suspicion of PA, blood tests, chest radiograph, and colonoscopy were performed without revealing abnormalities. Positron emission tomography and computed tomography also was performed, showing cervical, mesenteric, retroperitoneal, and inguinal adenopathies. Histologic examination of both inguinal adenectomy and cervical lymph node biopsy revealed Bcl-2-positive in situ follicular lymphoma (ISFL). Examination of an iliac crest marrow aspirate showed minimal involvement of lymphoma (10%). Follow-up imaging performed 4 months after diagnosis showed no changes. The patient was diagnosed with a low-grade chronic lymphoproliferative disorder with histologic findings consistent with ISFL presenting with small disperse adenopathies and minimal bone marrow involvement. The hematology department opted for a wait-and-see approach with 6-month follow-up imaging.

The skin lesions were first treated with salicylic acid cream 10%, psoralen plus UVA therapy, and methotrexate 20 mg weekly for 2 months without remission. Replacing the other therapies, we initiated acitretin 25 mg daily, achieving sustained remission after 6 months of treatment, and then continued with a scaled dose reduction. The patient remained lesion free 1 year after starting the treatment, with a daily dose of 10 mg of acitretin.

Paraneoplastic acrokeratosis has been traditionally described as a paraneoplastic entity mainly associated with primary squamous cell carcinoma (SCC) of the upper aerodigestive tract or a metastatic SCC of the cervical lymph nodes with an unknown origin.4,5 However, uncommon associations such as adenocarcinoma of the prostate, lung, esophagus, stomach, and colon; transitional cell carcinoma of the bladder; small cell carcinoma of the lung; cutaneous SCC; breast cancer; metastatic thymic carcinoma; metastatic neuroendocrine tumor; bronchial carcinoid tumor; SCC of the vulvar region; simultaneous multiple genitourinary tumors; and liposarcoma also have been described.6 Regarding the association with lymphoma, PA has been reported with peripheral T-cell lymphoma7 and Hodgkin disease8; however, ISFL underlying PA is rare.

Follicular lymphoma is the second most common non-Hodgkin lymphoma in Western countries and comprises approximately 20% of all lymphomas.9 It is slightly more prevalent in females, and the majority of patients present with advanced-stage disease. Generally considered to be an incurable disease, a watchful-waiting approach of conservative management has been advocated in most cases, deferring treatment until symptoms appear.9

Histology of PA is nonspecific, as in our case. However, it facilitates a differential diagnosis of major dermatoses including psoriasis vulgaris, pityriasis rubra pilaris, and lupus erythematosus.

Paraneoplastic palmoplantar keratoderma also is characteristic of Howel-Evans syndrome, which is a rare inherited condition associated with esophageal cancer. In contrast to our case, palmoplantar keratoderma in these patients usually begins around 10 years of age, is caused by a mutation in the RHBDF2 gene, and is inherited in an autosomal pattern.10

The diagnosis in our case was supported by a typical clinical picture, nonspecific histology, and the concurrent finding of the underlying lymphoma. Treatment of PA must focus on the removal of the underlying malignancy, which implies the remission of the cutaneous lesions. Taking into account that a recurrence of the primary tumor leads to a relapse of skin manifestations while distant metastases do not cause a reappearance of PA, it could be suggested that pathogenetically relevant factors are produced by the primary tumor and by lymph node metastases but not by metastases elsewhere.

In this case, due to the wait-and-see approach, a specific treatment for the skin lesions was established. Although management of the skin itself generally is ineffective, there are isolated reports of response after corticosteroids, antibiotics, antimycotics, keratolytic measures, or psoralen plus UVA therapy.6 Wishart11 used etretinate to achieve an improvement of PA. We also achieved good response with acitretin. Retinoids are known to have antineoplastic activity, which may have been helpful in both the patient we presented and the one reported by Wishart.11 In summary, we propose adding ISFL to the expanding list of malignant neoplasms associated with PA, noting the response of skin lesions after acitretin.

References
  1. Bazex A, Salvador R, Dupré A, et al. Syndrome paranéoplasique à type d'hyperkératose des extremités. Guérison après le traitement de l'épithelioma laryngé. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.
  2. Bazex A, Griffiths A. Acrokeratosis paraneoplasticae--a new cutaneous marker of malignancy. Br J Dermatol. 1980;103:301-306.
  3. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14:84-89.
  4. Witkowski JA, Parish LC. Bazex's syndrome. Paraneoplastic acrokeratosis. JAMA. 1982;248:2883-2884.
  5. Bolognia JL. Bazex's syndrome. Clin Dermatol. 1993;11:37-42.
  6. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma [published online August 28, 2006]. J Am Acad Dermatol. 2006;55:1103-1105.
  7. Lin YC, Chu CY, Chiu HC. Acrokeratosis paraneoplastica Bazex's  syndrome: unusual association with a peripheral T-cell lymphoma. Acta Derm Venereol. 2001;81:440-441.
  8. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol. 1995;133:322-325.
  9. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976-2984.
  10. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85:183-185.
  11. Wishart JM. Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol. 1986;115:595-599.
References
  1. Bazex A, Salvador R, Dupré A, et al. Syndrome paranéoplasique à type d'hyperkératose des extremités. Guérison après le traitement de l'épithelioma laryngé. Bull Soc Fr Dermatol Syphiligr. 1965;72:182.
  2. Bazex A, Griffiths A. Acrokeratosis paraneoplasticae--a new cutaneous marker of malignancy. Br J Dermatol. 1980;103:301-306.
  3. Bolognia JL. Bazex syndrome: acrokeratosis paraneoplastica. Semin Dermatol. 1995;14:84-89.
  4. Witkowski JA, Parish LC. Bazex's syndrome. Paraneoplastic acrokeratosis. JAMA. 1982;248:2883-2884.
  5. Bolognia JL. Bazex's syndrome. Clin Dermatol. 1993;11:37-42.
  6. Sator PG, Breier F, Gschnait F. Acrokeratosis paraneoplastica (Bazex's syndrome): association with liposarcoma [published online August 28, 2006]. J Am Acad Dermatol. 2006;55:1103-1105.
  7. Lin YC, Chu CY, Chiu HC. Acrokeratosis paraneoplastica Bazex's  syndrome: unusual association with a peripheral T-cell lymphoma. Acta Derm Venereol. 2001;81:440-441.
  8. Lucker GP, Steijlen PM. Acrokeratosis paraneoplastica (Bazex syndrome) occurring with acquired ichthyosis in Hodgkin's disease. Br J Dermatol. 1995;133:322-325.
  9. Jegalian AG, Eberle FC, Pack SD, et al. Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. Blood. 2011;118:2976-2984.
  10. Sroa N, Witman P. Howel-Evans syndrome: a variant of ectodermal dysplasia. Cutis. 2010;85:183-185.
  11. Wishart JM. Bazex paraneoplastic acrokeratosis: a case report and response to Tigason. Br J Dermatol. 1986;115:595-599.
Issue
Cutis - 100(2)
Issue
Cutis - 100(2)
Page Number
E3-E5
Page Number
E3-E5
Publications
Publications
Topics
Article Type
Display Headline
Paraneoplastic Acrokeratosis (Bazex Syndrome): Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin
Display Headline
Paraneoplastic Acrokeratosis (Bazex Syndrome): Unusual Association With In Situ Follicular Lymphoma and Response to Acitretin
Sections
Inside the Article

Practice Points

  • Paraneoplastic acrokeratosis may mimic palmo-plantar acrokeratosis in both clinical presentation and treatment.
  • Uncommon associations of paraneoplastic acrokeratosis with different types of lymphoma have been described.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media

Solitary Nodule With White Hairs

Article Type
Changed
Display Headline
Solitary Nodule With White Hairs

The Diagnosis: Trichofolliculoma

Microscopic examination revealed a dilated cystic follicle that communicated with the skin surface (Figure). The follicle was lined with squamous epithelium and surrounded by numerous secondary follicles, many of which contained a hair shaft. A diagnosis of trichofolliculoma was made.

Microscopic examination revealed a dilated cystic follicle that communicated with the skin surface (H&E, original magnification ×40).

Clinically, the differential diagnosis of a flesh-colored papule on the scalp with prominent follicle includes dilated pore of Winer, epidermoid cyst, pilar sheath acanthoma, and trichoepithelioma.1,2 Multiple hair shafts present in a single follicle may be seen in pili multigemini, tufted folliculitis, trichostasis spinulosa, and trichofolliculoma. On histopathologic examination, a dilated central follicle surrounded with smaller secondary follicles was identified, consistent with trichofolliculoma.

Trichofolliculoma is a rare follicular hamartoma typically occurring on the face, scalp, or trunk as a solitary papule or nodule due to the proliferation of abnormal hair follicle stem cells.3,4 It may present as a flesh-colored nodule with a central pore that may drain sebum or contain white vellus hairs. Trichofolliculoma is considered a benign entity, despite one case report of malignant transformation.5 Biopsy is diagnostic and no further treatment is needed. Recurrence rarely occurs at the primary site after surgical excision, which may be performed for cosmetic purposes or to alleviate functional impairment.

References
  1. Ghosh SK, Bandyopadhyay D, Barma KD. Perifollicular nodule on the face of a young man. Indian J Dermatol Venereol Leprol. 2011;77:531-533.  
  2. Gokalp H, Gurer MA, Alan S. Trichofolliculoma: a rare variant of hair follicle hamartoma. Dermatol Online J. 2013;19:19264.
  3. Choi CM, Lew BL, Sim WY. Multiple trichofolliculomas on unusual sites: a case report and review of the literature. Int J Dermatol. 2013;52:87-89.  
  4. Misago N, Kimura T, Toda S, et al. A revaluation of trichofolliculoma: the histopathological and immunohistochemical features. Am J Dermatopathol. 2010;32:35-43.
  5. Stem JB, Stout DA. Trichofolliculoma showing perineural invasion. trichofolliculocarcinoma? Arch Dermatol. 1979;115:1003-1004.
Article PDF
Author and Disclosure Information

Dr. Wetzel was from the University of Vermont, Burlington, and currently is from the Division of Dermatology, Department of Internal Medicine, University of Louisville School of Medicine, Kentucky. Drs. Gagnon and McDermott were from the University of Virginia, Charlottesville. Dr. Gagnon currently is from Dermatology PLC, Charlottesville and Orange, Virginia. Dr. McDermott currently is from the Department of Pathology and Laboratory Services, David Grant Medical Center, Fairfield, California.

The authors report no conflict of interest.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Air Force or the Department of Defense.

Correspondence: Megan Wetzel, MD, MPH, 3810 Springhurst Blvd, Louisville, KY 40241 ([email protected]). 

Issue
Cutis - 100(2)
Publications
Topics
Page Number
E1-E2
Sections
Author and Disclosure Information

Dr. Wetzel was from the University of Vermont, Burlington, and currently is from the Division of Dermatology, Department of Internal Medicine, University of Louisville School of Medicine, Kentucky. Drs. Gagnon and McDermott were from the University of Virginia, Charlottesville. Dr. Gagnon currently is from Dermatology PLC, Charlottesville and Orange, Virginia. Dr. McDermott currently is from the Department of Pathology and Laboratory Services, David Grant Medical Center, Fairfield, California.

The authors report no conflict of interest.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Air Force or the Department of Defense.

Correspondence: Megan Wetzel, MD, MPH, 3810 Springhurst Blvd, Louisville, KY 40241 ([email protected]). 

Author and Disclosure Information

Dr. Wetzel was from the University of Vermont, Burlington, and currently is from the Division of Dermatology, Department of Internal Medicine, University of Louisville School of Medicine, Kentucky. Drs. Gagnon and McDermott were from the University of Virginia, Charlottesville. Dr. Gagnon currently is from Dermatology PLC, Charlottesville and Orange, Virginia. Dr. McDermott currently is from the Department of Pathology and Laboratory Services, David Grant Medical Center, Fairfield, California.

The authors report no conflict of interest.

The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Air Force or the Department of Defense.

Correspondence: Megan Wetzel, MD, MPH, 3810 Springhurst Blvd, Louisville, KY 40241 ([email protected]). 

Article PDF
Article PDF
Related Articles

The Diagnosis: Trichofolliculoma

Microscopic examination revealed a dilated cystic follicle that communicated with the skin surface (Figure). The follicle was lined with squamous epithelium and surrounded by numerous secondary follicles, many of which contained a hair shaft. A diagnosis of trichofolliculoma was made.

Microscopic examination revealed a dilated cystic follicle that communicated with the skin surface (H&E, original magnification ×40).

Clinically, the differential diagnosis of a flesh-colored papule on the scalp with prominent follicle includes dilated pore of Winer, epidermoid cyst, pilar sheath acanthoma, and trichoepithelioma.1,2 Multiple hair shafts present in a single follicle may be seen in pili multigemini, tufted folliculitis, trichostasis spinulosa, and trichofolliculoma. On histopathologic examination, a dilated central follicle surrounded with smaller secondary follicles was identified, consistent with trichofolliculoma.

Trichofolliculoma is a rare follicular hamartoma typically occurring on the face, scalp, or trunk as a solitary papule or nodule due to the proliferation of abnormal hair follicle stem cells.3,4 It may present as a flesh-colored nodule with a central pore that may drain sebum or contain white vellus hairs. Trichofolliculoma is considered a benign entity, despite one case report of malignant transformation.5 Biopsy is diagnostic and no further treatment is needed. Recurrence rarely occurs at the primary site after surgical excision, which may be performed for cosmetic purposes or to alleviate functional impairment.

The Diagnosis: Trichofolliculoma

Microscopic examination revealed a dilated cystic follicle that communicated with the skin surface (Figure). The follicle was lined with squamous epithelium and surrounded by numerous secondary follicles, many of which contained a hair shaft. A diagnosis of trichofolliculoma was made.

Microscopic examination revealed a dilated cystic follicle that communicated with the skin surface (H&E, original magnification ×40).

Clinically, the differential diagnosis of a flesh-colored papule on the scalp with prominent follicle includes dilated pore of Winer, epidermoid cyst, pilar sheath acanthoma, and trichoepithelioma.1,2 Multiple hair shafts present in a single follicle may be seen in pili multigemini, tufted folliculitis, trichostasis spinulosa, and trichofolliculoma. On histopathologic examination, a dilated central follicle surrounded with smaller secondary follicles was identified, consistent with trichofolliculoma.

Trichofolliculoma is a rare follicular hamartoma typically occurring on the face, scalp, or trunk as a solitary papule or nodule due to the proliferation of abnormal hair follicle stem cells.3,4 It may present as a flesh-colored nodule with a central pore that may drain sebum or contain white vellus hairs. Trichofolliculoma is considered a benign entity, despite one case report of malignant transformation.5 Biopsy is diagnostic and no further treatment is needed. Recurrence rarely occurs at the primary site after surgical excision, which may be performed for cosmetic purposes or to alleviate functional impairment.

References
  1. Ghosh SK, Bandyopadhyay D, Barma KD. Perifollicular nodule on the face of a young man. Indian J Dermatol Venereol Leprol. 2011;77:531-533.  
  2. Gokalp H, Gurer MA, Alan S. Trichofolliculoma: a rare variant of hair follicle hamartoma. Dermatol Online J. 2013;19:19264.
  3. Choi CM, Lew BL, Sim WY. Multiple trichofolliculomas on unusual sites: a case report and review of the literature. Int J Dermatol. 2013;52:87-89.  
  4. Misago N, Kimura T, Toda S, et al. A revaluation of trichofolliculoma: the histopathological and immunohistochemical features. Am J Dermatopathol. 2010;32:35-43.
  5. Stem JB, Stout DA. Trichofolliculoma showing perineural invasion. trichofolliculocarcinoma? Arch Dermatol. 1979;115:1003-1004.
References
  1. Ghosh SK, Bandyopadhyay D, Barma KD. Perifollicular nodule on the face of a young man. Indian J Dermatol Venereol Leprol. 2011;77:531-533.  
  2. Gokalp H, Gurer MA, Alan S. Trichofolliculoma: a rare variant of hair follicle hamartoma. Dermatol Online J. 2013;19:19264.
  3. Choi CM, Lew BL, Sim WY. Multiple trichofolliculomas on unusual sites: a case report and review of the literature. Int J Dermatol. 2013;52:87-89.  
  4. Misago N, Kimura T, Toda S, et al. A revaluation of trichofolliculoma: the histopathological and immunohistochemical features. Am J Dermatopathol. 2010;32:35-43.
  5. Stem JB, Stout DA. Trichofolliculoma showing perineural invasion. trichofolliculocarcinoma? Arch Dermatol. 1979;115:1003-1004.
Issue
Cutis - 100(2)
Issue
Cutis - 100(2)
Page Number
E1-E2
Page Number
E1-E2
Publications
Publications
Topics
Article Type
Display Headline
Solitary Nodule With White Hairs
Display Headline
Solitary Nodule With White Hairs
Sections
Questionnaire Body

A 72-year-old man presented with a new asymptomatic 0.7-cm flesh-colored papule with a central tuft of white hairs on the posterior scalp. The remainder of the physical examination was unremarkable. Biopsy for histopathologic examination was performed to confirm diagnosis.

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
PubMed ID
28961295
Disqus Comments
Default
Article PDF Media

Pruritic Eruption on the Chest

Article Type
Changed
Display Headline
Pruritic Eruption on the Chest

The Diagnosis: Grover Disease

Grover disease (also known as transient acantholytic dermatosis) was first described by Ralph W. Grover in 1970 as an idiopathic, acquired, monomorphous, papulovesicular eruption. Although originally characterized by solely transient acantholytic dermatosis, over time the term Grover disease has been expanded to include persistent acantholytic dermatoses. Grover disease chiefly affects white adults older than 40 years and is more prevalent in males than females. Cases generally are self-limited but correlate with age, as older adults are more likely to have prolonged eruptions.1

Grover disease typically erupts with discrete, erythematous, edematous, acneform, red-brown or flesh-colored papules, papulovesicles, or keratotic papules that primarily are seen on the trunk and anterior portion of the chest. As the rash spreads, it can erupt on the neck and thighs. The etiology of Grover disease is unknown, but many factors have been associated with the condition in a limited number of patients, including exposure to UV radiation, excessive heat or sweating, use of sulfadoxine-pyrimethamine and recombinant human IL-4, and infection with Malassezia furfur and Demodex folliculorum.1 Grover disease also has been associated with other conditions such as asteatotic eczema, allergic contact dermatitis, and atopic dermatitis.2

Histologically, Grover disease (Figure 1) is an acantholytic process that can exhibit dyskeratosis (corps ronds and grains). Foci often are small and multiple foci are seen on shave biopsy. There also may be spongiotic changes when associated with an eczematous element. A perivascular lymphohistiocytic infiltrate with eosinophils usually is seen.3 Basket weave keratin may be seen; however, as the lesions cause pruritus, erosions and ulcerations often are present.4

Figure 1. Grover disease. In the Darier-like pattern, there are multiple small foci (white arrows) of acantholysis and dyskeratosis. An inflammatory cell infiltrate, often with eosinophils, is seen in the dermis (black arrow)(H&E, original magnification ×200).

Grover disease has multiple histologic variants that may resemble Darier disease, Hailey-Hailey disease, pemphigus foliaceus, pemphigus vulgaris, and spongiotic dermatitis and can present in combination.5

The variant of Grover disease that has a Darier-like pattern is difficult to distinguish from Darier disease, an autosomal-dominant-inherited disorder classified by small papules that emerge in seborrheic areas during childhood and adolescence. Histologically, Darier disease (Figure 2) shows broad areas of dyskeratosis and acantholysis that lead to suprabasal cleavage. Follicular extension may be present. In addition, there often is prominent vertical parakeratosis in Darier disease.6 Histologic features that favor Darier disease over the Darier-like variant of Grover disease include a broad focus of acanthotic dyskeratosis with follicular extension; the presence of a hyperkeratotic stratum corneum; and a lack of spongiosis and eosinophils, which are notably absent in Darier disease but may be present in Grover disease.4

Figure 2. Darier disease. There is a broad suprabasal cleft with over-lying acantholysis and dyskeratosis (corps ronds and grains). A thick keratotic plug with parakeratosis overlies the acantholytic dyskeratosis (H&E, original magnification ×100).

Another variant of Grover disease has a Hailey-Hailey-like pattern, which is characterized by Hailey-Hailey disease's dilapidated brick wall appearance or the diffuse suprabasal acantholysis of all epidermal layers without notable dyskeratosis.4 Hailey-Hailey disease, also known as familial benign pemphigus, is an autosomal-dominant disorder that presents with erythematous vesicular plaques in flexural areas. The plaques progress to flaccid bullae with rupture and crusting and spread peripherally.7 Pathology shows suprabasilar clefts and numerous acantholytic cells (Figure 3). Dyskeratotic keratinocytes are rare with infrequent corps ronds and rare grains. The epidermis also is less hyperplastic in Grover disease than in Hailey-Hailey disease.1

Figure 3. Hailey-Hailey disease. Acantholysis is seen at all levels of the epidermis giving the impression of a dilapidated brick wall (H&E, original magnification ×200).

Grover disease also may present histologically with a pemphiguslike pattern, mimicking pemphigus foliaceus and pemphigus vulgaris; however, direct immunofluorescence studies are negative in Grover disease.

Pemphigus foliaceus is an autoimmune disorder caused by autoantibodies to desmoglein 1, which are present on the surfaces of keratinocytes, and is characterized by scaly crusts and blisters.8 Histologically, pemphigus foliaceus (Figure 4) shows a superficial epidermal blistering process. The acantholysis may be subtle and is commonly localized to the stratum granulosum, extending into the stratum corneum. Complete loss of the stratum corneum can be seen, resulting in only scattered acantholytic cells. Spongiosis also may be seen. The dermis shows a perivascular infiltrate that often contains eosinophils. Pemphigus foliaceus is confirmed by direct immunofluorescence.9

Figure 4. Pemphigus foliaceus. An intragranular blister is seen with acantholysis of keratinocytes (H&E, original magnification ×200).

Pemphigus vulgaris is an autoimmune blistering disorder that is characterized by IgG autoantibodies to desmoglein 3, a component of desmosomes that are involved in keratinocyte-to-keratinocyte adhesion. Clinically, patients present with flaccid fragile blisters on the skin and mucous membranes that rupture easily, leading to painful erosions.10 Intraepidermal blisters are seen histologically (Figure 5) with the loss of cohesion (acantholysis) seen classically in the lower portions of the epidermis where desmoglein 3 is most prominent. When only the basal layer remains, the histology has been likened to a tombstone row.11 Extension of the blister along the adnexa is common. The underlying dermis shows a perivascular infiltrate with eosinophils. Early lesions may show only eosinophilic spongiosis. Direct immunofluorescence studies show IgG and C3 in an intercellular pattern that resembles a fish net or chicken wire.4,11

Figure 5. Pemphigus vulgaris. An intraepidermal blister is present immediately above the basal layer leaving a tombstone row of basilar keratinocytes. The separation is seen tracking down a hair follicle (black arrow). Eosinophils are seen in a spongiotic focus (blue arrow)(H&E, original magnification ×200).

The spongioticlike pattern of Grover disease is marked by epidermal edema with separation of the keratinocytes and the revelation of their intracellular bridges,4 which manifests as vesiculation in the stratum corneum or upper layers of the epidermis.12

Grover disease is self-limited and may spontaneously resolve; however, the disease may be responsive to topical and systemic steroids. Additionally, avoidance of aggravating factors such as sunlight, heat, and sweating can improve symptoms.2

References
  1. Parsons JM. Transient acantholytic dermatosis (Grover's disease): a global perspective. J Am Acad Dermatol. 1996;35(5, pt 1):653-666; quiz 667-670.
  2. Quirk CJ, Heenan PJ. Grover's disease: 34 years on. Australas J Dermatol. 2004;45:83-86.
  3. Davis MD, Dinneen AM, Landa N, et al. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc. 1999;74:229-234.
  4. Weaver J, Bergfeld WF. Grover disease (transient acantholytic dermatosis). Arch Pathol Lab Med. 2009;133:1490-1494.  
  5. Chalet M, Grover R, Ackerman AB. Transient acantholytic dermatosis: a reevaluation. Arch Dermatol. 1977;133:431-435.
  6. Takagi A, Kamijo M, Ikeda S. Darier disease. J Dermatol. 2016;43:275-279.
  7. Engin B, Kutlubay Z, Celik U, et al. Hailey-Hailey disease: a fold (intertriginous) dermatosis. Clin Dermatol. 2015;33:452-455.
  8. de Sena Nogueira Maehara L, Huizinga J, Jonkman MF. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature [published online March 31, 2015]. Br J Dermatol. 2015;172:1420-1423.
  9. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29:405-412.
  10. Black M, Mignogna MD, Scully C. Number II. pemphigus vulgaris. Oral Dis. 2005;11:119-130.
  11. Madke B, Doshi B, Khopkar U, et al. Appearances in dermatopathology: the diagnostic and the deceptive. Indian J Dermatol Venerol Leprol. 2013;79:338-348.
  12. Motaparthi K. Pseudoherpetic transient acantholytic dermatosis (Grover disease): case series and review of the literature [published online February 16, 2017]. J Cutan Pathol. 2017;44:486-489.
Article PDF
Author and Disclosure Information

From the Department of Dermatology, Saint Louis University School of Medicine, Missouri. Dr. Vidal also is from the Department of Pathology.

The authors report no conflict of interest. 

Correspondence: Claudia I. Vidal, MD, PhD, SSM Health Saint Louis University Hospital - South Campus, 1755 S Grand Blvd, St Louis, MO 63104 ([email protected]).

Issue
Cutis - 100(2)
Publications
Topics
Page Number
84, 94-96
Sections
Author and Disclosure Information

From the Department of Dermatology, Saint Louis University School of Medicine, Missouri. Dr. Vidal also is from the Department of Pathology.

The authors report no conflict of interest. 

Correspondence: Claudia I. Vidal, MD, PhD, SSM Health Saint Louis University Hospital - South Campus, 1755 S Grand Blvd, St Louis, MO 63104 ([email protected]).

Author and Disclosure Information

From the Department of Dermatology, Saint Louis University School of Medicine, Missouri. Dr. Vidal also is from the Department of Pathology.

The authors report no conflict of interest. 

Correspondence: Claudia I. Vidal, MD, PhD, SSM Health Saint Louis University Hospital - South Campus, 1755 S Grand Blvd, St Louis, MO 63104 ([email protected]).

Article PDF
Article PDF
Related Articles

The Diagnosis: Grover Disease

Grover disease (also known as transient acantholytic dermatosis) was first described by Ralph W. Grover in 1970 as an idiopathic, acquired, monomorphous, papulovesicular eruption. Although originally characterized by solely transient acantholytic dermatosis, over time the term Grover disease has been expanded to include persistent acantholytic dermatoses. Grover disease chiefly affects white adults older than 40 years and is more prevalent in males than females. Cases generally are self-limited but correlate with age, as older adults are more likely to have prolonged eruptions.1

Grover disease typically erupts with discrete, erythematous, edematous, acneform, red-brown or flesh-colored papules, papulovesicles, or keratotic papules that primarily are seen on the trunk and anterior portion of the chest. As the rash spreads, it can erupt on the neck and thighs. The etiology of Grover disease is unknown, but many factors have been associated with the condition in a limited number of patients, including exposure to UV radiation, excessive heat or sweating, use of sulfadoxine-pyrimethamine and recombinant human IL-4, and infection with Malassezia furfur and Demodex folliculorum.1 Grover disease also has been associated with other conditions such as asteatotic eczema, allergic contact dermatitis, and atopic dermatitis.2

Histologically, Grover disease (Figure 1) is an acantholytic process that can exhibit dyskeratosis (corps ronds and grains). Foci often are small and multiple foci are seen on shave biopsy. There also may be spongiotic changes when associated with an eczematous element. A perivascular lymphohistiocytic infiltrate with eosinophils usually is seen.3 Basket weave keratin may be seen; however, as the lesions cause pruritus, erosions and ulcerations often are present.4

Figure 1. Grover disease. In the Darier-like pattern, there are multiple small foci (white arrows) of acantholysis and dyskeratosis. An inflammatory cell infiltrate, often with eosinophils, is seen in the dermis (black arrow)(H&E, original magnification ×200).

Grover disease has multiple histologic variants that may resemble Darier disease, Hailey-Hailey disease, pemphigus foliaceus, pemphigus vulgaris, and spongiotic dermatitis and can present in combination.5

The variant of Grover disease that has a Darier-like pattern is difficult to distinguish from Darier disease, an autosomal-dominant-inherited disorder classified by small papules that emerge in seborrheic areas during childhood and adolescence. Histologically, Darier disease (Figure 2) shows broad areas of dyskeratosis and acantholysis that lead to suprabasal cleavage. Follicular extension may be present. In addition, there often is prominent vertical parakeratosis in Darier disease.6 Histologic features that favor Darier disease over the Darier-like variant of Grover disease include a broad focus of acanthotic dyskeratosis with follicular extension; the presence of a hyperkeratotic stratum corneum; and a lack of spongiosis and eosinophils, which are notably absent in Darier disease but may be present in Grover disease.4

Figure 2. Darier disease. There is a broad suprabasal cleft with over-lying acantholysis and dyskeratosis (corps ronds and grains). A thick keratotic plug with parakeratosis overlies the acantholytic dyskeratosis (H&E, original magnification ×100).

Another variant of Grover disease has a Hailey-Hailey-like pattern, which is characterized by Hailey-Hailey disease's dilapidated brick wall appearance or the diffuse suprabasal acantholysis of all epidermal layers without notable dyskeratosis.4 Hailey-Hailey disease, also known as familial benign pemphigus, is an autosomal-dominant disorder that presents with erythematous vesicular plaques in flexural areas. The plaques progress to flaccid bullae with rupture and crusting and spread peripherally.7 Pathology shows suprabasilar clefts and numerous acantholytic cells (Figure 3). Dyskeratotic keratinocytes are rare with infrequent corps ronds and rare grains. The epidermis also is less hyperplastic in Grover disease than in Hailey-Hailey disease.1

Figure 3. Hailey-Hailey disease. Acantholysis is seen at all levels of the epidermis giving the impression of a dilapidated brick wall (H&E, original magnification ×200).

Grover disease also may present histologically with a pemphiguslike pattern, mimicking pemphigus foliaceus and pemphigus vulgaris; however, direct immunofluorescence studies are negative in Grover disease.

Pemphigus foliaceus is an autoimmune disorder caused by autoantibodies to desmoglein 1, which are present on the surfaces of keratinocytes, and is characterized by scaly crusts and blisters.8 Histologically, pemphigus foliaceus (Figure 4) shows a superficial epidermal blistering process. The acantholysis may be subtle and is commonly localized to the stratum granulosum, extending into the stratum corneum. Complete loss of the stratum corneum can be seen, resulting in only scattered acantholytic cells. Spongiosis also may be seen. The dermis shows a perivascular infiltrate that often contains eosinophils. Pemphigus foliaceus is confirmed by direct immunofluorescence.9

Figure 4. Pemphigus foliaceus. An intragranular blister is seen with acantholysis of keratinocytes (H&E, original magnification ×200).

Pemphigus vulgaris is an autoimmune blistering disorder that is characterized by IgG autoantibodies to desmoglein 3, a component of desmosomes that are involved in keratinocyte-to-keratinocyte adhesion. Clinically, patients present with flaccid fragile blisters on the skin and mucous membranes that rupture easily, leading to painful erosions.10 Intraepidermal blisters are seen histologically (Figure 5) with the loss of cohesion (acantholysis) seen classically in the lower portions of the epidermis where desmoglein 3 is most prominent. When only the basal layer remains, the histology has been likened to a tombstone row.11 Extension of the blister along the adnexa is common. The underlying dermis shows a perivascular infiltrate with eosinophils. Early lesions may show only eosinophilic spongiosis. Direct immunofluorescence studies show IgG and C3 in an intercellular pattern that resembles a fish net or chicken wire.4,11

Figure 5. Pemphigus vulgaris. An intraepidermal blister is present immediately above the basal layer leaving a tombstone row of basilar keratinocytes. The separation is seen tracking down a hair follicle (black arrow). Eosinophils are seen in a spongiotic focus (blue arrow)(H&E, original magnification ×200).

The spongioticlike pattern of Grover disease is marked by epidermal edema with separation of the keratinocytes and the revelation of their intracellular bridges,4 which manifests as vesiculation in the stratum corneum or upper layers of the epidermis.12

Grover disease is self-limited and may spontaneously resolve; however, the disease may be responsive to topical and systemic steroids. Additionally, avoidance of aggravating factors such as sunlight, heat, and sweating can improve symptoms.2

The Diagnosis: Grover Disease

Grover disease (also known as transient acantholytic dermatosis) was first described by Ralph W. Grover in 1970 as an idiopathic, acquired, monomorphous, papulovesicular eruption. Although originally characterized by solely transient acantholytic dermatosis, over time the term Grover disease has been expanded to include persistent acantholytic dermatoses. Grover disease chiefly affects white adults older than 40 years and is more prevalent in males than females. Cases generally are self-limited but correlate with age, as older adults are more likely to have prolonged eruptions.1

Grover disease typically erupts with discrete, erythematous, edematous, acneform, red-brown or flesh-colored papules, papulovesicles, or keratotic papules that primarily are seen on the trunk and anterior portion of the chest. As the rash spreads, it can erupt on the neck and thighs. The etiology of Grover disease is unknown, but many factors have been associated with the condition in a limited number of patients, including exposure to UV radiation, excessive heat or sweating, use of sulfadoxine-pyrimethamine and recombinant human IL-4, and infection with Malassezia furfur and Demodex folliculorum.1 Grover disease also has been associated with other conditions such as asteatotic eczema, allergic contact dermatitis, and atopic dermatitis.2

Histologically, Grover disease (Figure 1) is an acantholytic process that can exhibit dyskeratosis (corps ronds and grains). Foci often are small and multiple foci are seen on shave biopsy. There also may be spongiotic changes when associated with an eczematous element. A perivascular lymphohistiocytic infiltrate with eosinophils usually is seen.3 Basket weave keratin may be seen; however, as the lesions cause pruritus, erosions and ulcerations often are present.4

Figure 1. Grover disease. In the Darier-like pattern, there are multiple small foci (white arrows) of acantholysis and dyskeratosis. An inflammatory cell infiltrate, often with eosinophils, is seen in the dermis (black arrow)(H&E, original magnification ×200).

Grover disease has multiple histologic variants that may resemble Darier disease, Hailey-Hailey disease, pemphigus foliaceus, pemphigus vulgaris, and spongiotic dermatitis and can present in combination.5

The variant of Grover disease that has a Darier-like pattern is difficult to distinguish from Darier disease, an autosomal-dominant-inherited disorder classified by small papules that emerge in seborrheic areas during childhood and adolescence. Histologically, Darier disease (Figure 2) shows broad areas of dyskeratosis and acantholysis that lead to suprabasal cleavage. Follicular extension may be present. In addition, there often is prominent vertical parakeratosis in Darier disease.6 Histologic features that favor Darier disease over the Darier-like variant of Grover disease include a broad focus of acanthotic dyskeratosis with follicular extension; the presence of a hyperkeratotic stratum corneum; and a lack of spongiosis and eosinophils, which are notably absent in Darier disease but may be present in Grover disease.4

Figure 2. Darier disease. There is a broad suprabasal cleft with over-lying acantholysis and dyskeratosis (corps ronds and grains). A thick keratotic plug with parakeratosis overlies the acantholytic dyskeratosis (H&E, original magnification ×100).

Another variant of Grover disease has a Hailey-Hailey-like pattern, which is characterized by Hailey-Hailey disease's dilapidated brick wall appearance or the diffuse suprabasal acantholysis of all epidermal layers without notable dyskeratosis.4 Hailey-Hailey disease, also known as familial benign pemphigus, is an autosomal-dominant disorder that presents with erythematous vesicular plaques in flexural areas. The plaques progress to flaccid bullae with rupture and crusting and spread peripherally.7 Pathology shows suprabasilar clefts and numerous acantholytic cells (Figure 3). Dyskeratotic keratinocytes are rare with infrequent corps ronds and rare grains. The epidermis also is less hyperplastic in Grover disease than in Hailey-Hailey disease.1

Figure 3. Hailey-Hailey disease. Acantholysis is seen at all levels of the epidermis giving the impression of a dilapidated brick wall (H&E, original magnification ×200).

Grover disease also may present histologically with a pemphiguslike pattern, mimicking pemphigus foliaceus and pemphigus vulgaris; however, direct immunofluorescence studies are negative in Grover disease.

Pemphigus foliaceus is an autoimmune disorder caused by autoantibodies to desmoglein 1, which are present on the surfaces of keratinocytes, and is characterized by scaly crusts and blisters.8 Histologically, pemphigus foliaceus (Figure 4) shows a superficial epidermal blistering process. The acantholysis may be subtle and is commonly localized to the stratum granulosum, extending into the stratum corneum. Complete loss of the stratum corneum can be seen, resulting in only scattered acantholytic cells. Spongiosis also may be seen. The dermis shows a perivascular infiltrate that often contains eosinophils. Pemphigus foliaceus is confirmed by direct immunofluorescence.9

Figure 4. Pemphigus foliaceus. An intragranular blister is seen with acantholysis of keratinocytes (H&E, original magnification ×200).

Pemphigus vulgaris is an autoimmune blistering disorder that is characterized by IgG autoantibodies to desmoglein 3, a component of desmosomes that are involved in keratinocyte-to-keratinocyte adhesion. Clinically, patients present with flaccid fragile blisters on the skin and mucous membranes that rupture easily, leading to painful erosions.10 Intraepidermal blisters are seen histologically (Figure 5) with the loss of cohesion (acantholysis) seen classically in the lower portions of the epidermis where desmoglein 3 is most prominent. When only the basal layer remains, the histology has been likened to a tombstone row.11 Extension of the blister along the adnexa is common. The underlying dermis shows a perivascular infiltrate with eosinophils. Early lesions may show only eosinophilic spongiosis. Direct immunofluorescence studies show IgG and C3 in an intercellular pattern that resembles a fish net or chicken wire.4,11

Figure 5. Pemphigus vulgaris. An intraepidermal blister is present immediately above the basal layer leaving a tombstone row of basilar keratinocytes. The separation is seen tracking down a hair follicle (black arrow). Eosinophils are seen in a spongiotic focus (blue arrow)(H&E, original magnification ×200).

The spongioticlike pattern of Grover disease is marked by epidermal edema with separation of the keratinocytes and the revelation of their intracellular bridges,4 which manifests as vesiculation in the stratum corneum or upper layers of the epidermis.12

Grover disease is self-limited and may spontaneously resolve; however, the disease may be responsive to topical and systemic steroids. Additionally, avoidance of aggravating factors such as sunlight, heat, and sweating can improve symptoms.2

References
  1. Parsons JM. Transient acantholytic dermatosis (Grover's disease): a global perspective. J Am Acad Dermatol. 1996;35(5, pt 1):653-666; quiz 667-670.
  2. Quirk CJ, Heenan PJ. Grover's disease: 34 years on. Australas J Dermatol. 2004;45:83-86.
  3. Davis MD, Dinneen AM, Landa N, et al. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc. 1999;74:229-234.
  4. Weaver J, Bergfeld WF. Grover disease (transient acantholytic dermatosis). Arch Pathol Lab Med. 2009;133:1490-1494.  
  5. Chalet M, Grover R, Ackerman AB. Transient acantholytic dermatosis: a reevaluation. Arch Dermatol. 1977;133:431-435.
  6. Takagi A, Kamijo M, Ikeda S. Darier disease. J Dermatol. 2016;43:275-279.
  7. Engin B, Kutlubay Z, Celik U, et al. Hailey-Hailey disease: a fold (intertriginous) dermatosis. Clin Dermatol. 2015;33:452-455.
  8. de Sena Nogueira Maehara L, Huizinga J, Jonkman MF. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature [published online March 31, 2015]. Br J Dermatol. 2015;172:1420-1423.
  9. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29:405-412.
  10. Black M, Mignogna MD, Scully C. Number II. pemphigus vulgaris. Oral Dis. 2005;11:119-130.
  11. Madke B, Doshi B, Khopkar U, et al. Appearances in dermatopathology: the diagnostic and the deceptive. Indian J Dermatol Venerol Leprol. 2013;79:338-348.
  12. Motaparthi K. Pseudoherpetic transient acantholytic dermatosis (Grover disease): case series and review of the literature [published online February 16, 2017]. J Cutan Pathol. 2017;44:486-489.
References
  1. Parsons JM. Transient acantholytic dermatosis (Grover's disease): a global perspective. J Am Acad Dermatol. 1996;35(5, pt 1):653-666; quiz 667-670.
  2. Quirk CJ, Heenan PJ. Grover's disease: 34 years on. Australas J Dermatol. 2004;45:83-86.
  3. Davis MD, Dinneen AM, Landa N, et al. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc. 1999;74:229-234.
  4. Weaver J, Bergfeld WF. Grover disease (transient acantholytic dermatosis). Arch Pathol Lab Med. 2009;133:1490-1494.  
  5. Chalet M, Grover R, Ackerman AB. Transient acantholytic dermatosis: a reevaluation. Arch Dermatol. 1977;133:431-435.
  6. Takagi A, Kamijo M, Ikeda S. Darier disease. J Dermatol. 2016;43:275-279.
  7. Engin B, Kutlubay Z, Celik U, et al. Hailey-Hailey disease: a fold (intertriginous) dermatosis. Clin Dermatol. 2015;33:452-455.
  8. de Sena Nogueira Maehara L, Huizinga J, Jonkman MF. Rituximab therapy in pemphigus foliaceus: report of 12 cases and review of recent literature [published online March 31, 2015]. Br J Dermatol. 2015;172:1420-1423.
  9. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin. 2011;29:405-412.
  10. Black M, Mignogna MD, Scully C. Number II. pemphigus vulgaris. Oral Dis. 2005;11:119-130.
  11. Madke B, Doshi B, Khopkar U, et al. Appearances in dermatopathology: the diagnostic and the deceptive. Indian J Dermatol Venerol Leprol. 2013;79:338-348.
  12. Motaparthi K. Pseudoherpetic transient acantholytic dermatosis (Grover disease): case series and review of the literature [published online February 16, 2017]. J Cutan Pathol. 2017;44:486-489.
Issue
Cutis - 100(2)
Issue
Cutis - 100(2)
Page Number
84, 94-96
Page Number
84, 94-96
Publications
Publications
Topics
Article Type
Display Headline
Pruritic Eruption on the Chest
Display Headline
Pruritic Eruption on the Chest
Sections
Questionnaire Body

H&E, original magnification ×200.

A 55-year-old man presented with small, erythematous, nonfollicular, pruritic papules on the mid chest. 
 

Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article PDF Media